The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study

Authors

Gary J. Weil, Washington University School of Medicine in St. Louis
Joshua Bogus, Washington University School of Medicine in St. Louis
Peter U. Fischer, Washington University School of Medicine in St. Louis
Charles W. Goss, Washington University School of Medicine in St. Louis
K. O'Brian, Washington University School of Medicine in St. Louis
Kenneth B. Schechtman, Washington University School of Medicine in St. Louis
DOLF IDA Safety Study Group
et al.

Journal

PLoS Medicine

Publication Date

2019

Volume

16

Issue

6

First Page

e1002839

Document Type

Open Access Publication

DOI

10.1371/journal.pmed.1002839

Rights and Permissions

Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y, et al. (2019) The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. PLOS Medicine 16(6): e1002839. https://doi.org/10.1371/journal.pmed.1002839

Recommended Citation

Weil, Gary J.; Bogus, Joshua; Fischer, Peter U.; Goss, Charles W.; O'Brian, K.; Schechtman, Kenneth B.; DOLF IDA Safety Study Group; and et al., "The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study." PLoS Medicine. 16, 6. e1002839 (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8058